nemolizumab nemolizumab nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis. it is a monoclonal antibody that blocks the interleukin-31 receptor a. results of a phase ii clinical trial were published in march 2017. nemolizumabmonoclonal antibodytypewhole antibodysourcehumanizedtargetil31raclinical dataother namescim-331routes ofadministrationsubcutaneous injectionatc codenonelegal statuslegal status investigational pharmacokinetic datametabolismproteolytic enzymesidentifierscas number1476039-58-3chemspidernoneuniign465u8b72keggd11080 nemolizumab was invented by chugai, who sold an exclusive license for the drug's development and worldwide marketing (except japan and taiwan) to galderma in 2016.